Pipeline Digest meets specialty drug market needs
When AscellaHealth released its Q3 2023 Specialty & Rare Pipeline Digest, an expert resource for FDA approval status of specialty pharmaceuticals and cell and gene therapies (CGT), this complimentary, digital source of industry information elevated support for the specialty drug market needs of all stakeholders and decision makers, including pharmaceutical manufacturers, payers, providers and retail
